Does Catabasis Pharmaceuticals Inc’s (NASDAQ:CATB) Earnings Growth Make It An Outperformer?

For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Catabasis Pharmaceuticals Inc’s (NASDAQ:CATB) track record on a high level, to give you some insight into how the company has been performing against its long term trend and its industry peers. View our latest analysis for Catabasis Pharmaceuticals

Did CATB’s recent earnings growth beat the long-term trend and the industry?

I use the ‘latest twelve-month’ data, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. This technique enables me to assess different companies on a similar basis, using the most relevant data points. For Catabasis Pharmaceuticals, its latest earnings (trailing twelve month) is -US$27.14M, which, in comparison to the prior year’s figure, has become less negative. Given that these values are somewhat short-term thinking, I have calculated an annualized five-year value for CATB’s earnings, which stands at -US$28.58M. This suggests that, while net income is negative, it has become less negative over the years.

NasdaqGM:CATB Income Statement May 22nd 18
NasdaqGM:CATB Income Statement May 22nd 18
We can further analyze Catabasis Pharmaceuticals’s loss by looking at what the industry has been experiencing over the past few years. Each year, for the past five years Catabasis Pharmaceuticals’s top-line more than doubled on average, signalling that the business is in a high-growth phase with expenses racing ahead revenues, leading to annual losses. Inspecting growth from a sector-level, the US biotechs industry has been growing its average earnings by double-digit 21.75% in the prior twelve months, and 18.58% over the last five years. This shows that any uplift the industry is enjoying, Catabasis Pharmaceuticals has not been able to gain as much as its industry peers.

What does this mean?

Though Catabasis Pharmaceuticals’s past data is helpful, it is only one aspect of my investment thesis. Companies that incur net loss is always hard to envisage what will occur going forward, and when. The most valuable step is to assess company-specific issues Catabasis Pharmaceuticals may be facing and whether management guidance has steadily been met in the past. I recommend you continue to research Catabasis Pharmaceuticals to get a better picture of the stock by looking at:

  1. Future Outlook: What are well-informed industry analysts predicting for CATB’s future growth? Take a look at our free research report of analyst consensus for CATB’s outlook.
  2. Financial Health: Is CATB’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
NB: Figures in this article are calculated using data from the trailing twelve months from 31 March 2018. This may not be consistent with full year annual report figures.